Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
AML 2521 Trial: Venetoclax & Azacitidine for MRD-Positive #AML
HealthTreeDescription
Dr. Chiara Sartor from Bologna University Hospital explains the AML 2521 clinical trial for NPM1-mutated AML with measurable residual disease (MRD).
Key Topics:
- Understanding MRD and NPM1-mutated AML
- Venetoclax and azacitidine combination therapy
- Trial results: 94% maintained remission, 80% achieved MRD reduction
- Safety profile and bridge to transplantation
- Overall survival: 95%, Progression-free survival: 89%
A safe and effective strategy to bridge AML patients to transplantation while maintaining remission.
Learn more: https://linktr.ee/HealthTreeUniversity
TIMESTAMPS:
0:00 Introduction & Trial Overview
0:16 What is MRD and NPM1-Mutated AML
0:57 Treatment Strategy: Venetoclax & Azacitidine
1:15 Trial Results & Response Rates
1:48 Overall & Progression-Free Survival
2:08 Safety Profile & Adverse Events
#AML #ClinicalTrial #Leukemia #Venetoclax #CancerResearch